Tropisetron

Tropisetron

SCHEMBL18297

CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HTR3AHTR3BHTR3CHTR3DHTR3E

The experimentally established mechanism targets of Tropisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A known ✓ P46098 9/20 1.00
HTR3E known ✓ A5X5Y0 7/20 1.00
HTR3B known ✓ O95264 7/20 1.00
HTR3D known ✓ Q70Z44 7/20 1.00
HTR3C known ✓ Q8WXA8 7/20 1.00
KCNH2 Q12809 4/20 1.00
CHRNA7 P36544 3/20 1.00
CHRNA1 P02708 2/20 1.00
CHRNG P07510 2/20 1.00
CYP3A4 P08684 2/20 1.00
CYP2D6 P10635 2/20 1.00
CHRNB1 P11230 2/20 1.00
CHRNB2 P17787 2/20 1.00
CHRNA3 P32297 2/20 1.00
CHRNA4 P43681 2/20 1.00
CHRND Q07001 2/20 1.00
MAPT P10636 2/20 1.00
LMNA P02545 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
SLC6A4 P31645 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tropisetron SCHEMBL18299 1.00 HTR3A (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL29405651 1.00 HTR3A (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL3953452 1.00 HTR3A (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL17766649 1.00 HTR3A (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL31061471 1.00 HTR3A (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL463128 1.00 HTR3A (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL29930627 1.00 HTR3A (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL6273985 0.99 APEX1 (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL669358 0.99 APEX1 (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C
Tropisetron SCHEMBL133873 0.99 APEX1 (1.00) HTR3AHTR3EHTR3BHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 20634 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144776-A1 COMBINATION THERAPY FOR A DOPAMINE AGONIST ALTO NEUROSCIENCE, INC. (US) 2026-05-28 US claimed
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
US-20260130929-A1 USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN) 2026-05-14 US claimed
WO-2026090164-A1 COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN KALLYOPE, INC. (US) 2026-04-30 WO claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
EP-4725483-A1 COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE Université de Bordeaux (FR) 2026-04-15 EP claimed
EP-4719552-A1 INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY Xizang Haisco Pharmaceutical Co., Ltd. (CN) 2026-04-08 EP claimed
EP-4719497-A1 METHODS FOR TREATING SSTR POSITIVE CANCER Rayzebio, Inc. (US) 2026-04-08 EP claimed
US-12594270-B2 Schizophrenic disorder treatment using combination therapy CAMBRIDGE COGNITION LIMITED (GB) 2026-04-07 US claimed
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-03-17 US claimed
WO-1997010823-A1 5-HT3 RECEPTOR ANTAGONISTS FOR DYSKINESIA GLAXO GROUP LIMITED (GB) 1997-03-27 WO claimed
US-5576317-A NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis PFIZER INC. (US) 1996-11-19 US claimed
CN-1132625-A NK-1 receptor antagonits and 5HT3 receptor antagonists for treatment of emesis PFIZER (US) 1996-10-09 CN claimed
EP-0715855-A2 NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis PFIZER INC. (US) 1996-06-12 EP claimed
EP-0481207-A1 Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors E.R. SQUIBB & SONS, INC. (US) 1992-04-22 EP claimed
EP-0477624-A1 Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors E.R. SQUIBB & SONS, INC. (US) 1992-04-01 EP claimed
EP-0477625-A1 Method for preventing or treating anxiety employing a combination of an ace inhibitor and a drug that acts at serotonin receptors E.R. SQUIBB & SONS, INC. (US) 1992-04-01 EP claimed
US-5098889-A Cognition activators, angiotensin converting enzyme inhibitors E. R. SQUIBB & SONS, INC. (US) 1992-03-24 US claimed
EP-0467365-A2 Use of a 5-hydroxytryptamine-3(5-HT3) receptor antagonist for the preparation of a pharmaceutical composition for treating urinary incontinence E.R. SQUIBB & SONS, INC. (US) 1992-01-22 EP claimed
US-5032578-A Administering inhibitors of angiotensin coverting enzyme to mammals E. R. SQUIBB & SONS, INC. (US) 1991-07-16 US claimed